Compass Therapeutics, Inc. Company Profile & Data: stocks, market cap, financials, digital and more

                        
Company
Compass Therapeutics, Inc.Headquarters: Boston, 
                        MA, United States
                    
Employees: 24
CEO: Dr. Thomas J. Schuetz M.D., Ph.D.

                                        NASDAQ: CMPX
                                    
                                                    +17.89%
                                                    
                                        OTC: CMPX
                                    
Market Cap$344.0 Million

                        USD as of Jan. 1, 2025
                    
                            Market Cap History

Compass Therapeutics, Inc. Categories

United States Healthcare Biotechnology
United States Healthcare United States Biotechnology

Compass Therapeutics, Inc. market capitalization over time

Evolution of Compass Therapeutics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Compass Therapeutics, Inc.

Top Competitors by Market Capitalization

Industry: Biotechnology

Company	Market Cap (USD)
Novo Nordisk	$622.07 B
Vertex Pharmaceuticals Incorporated	$113.24 B
CSL Limited	$95.75 B
Regeneron Pharmaceuticals, Inc.	$76.33 B
Marinomed Biotech AG	$56.13 B

Sector:

Company	Market Cap (USD)
Lilly	$689.42 B
Novo Nordisk	$622.07 B
UnitedHealth Group	$487.54 B
Johnson & Johnson	$353.05 B
AbbVie	$301.60 B

Detailed Description

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trial for colorectal and ovarian cancer; CTX-471, a monoclonal antibody product candidate that is in Phase I clinical trial for patients with solid tumors, such as small cell lung cancer and melanoma; and CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 for oncology area. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Top 1-year algo backtest: +327.04%

$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Financials

Last Financial Reports Date	Dec. 31, 2023
Revenue TTM	$0
EBITDA	$-49,664,000
Gross Profit TTM	$0
Profit Margin	0.00%
Operating Margin	0.00%
Quarterly Revenue Growth	%